Mesoblast logo

Mesoblast

MESO | NASDAQ
Chart Builder DCF Calculator
$12.45
-$0.82 (-6.18%)
At close: Nov 16, 2026, 4:00 PM ET
$12.45
$0.00 (0.00%)
After-hours: Nov 16, 2026, 4:15 PM ET
-6.18%

Rating

Updated: Nov 16, 2026
53.6
-0.2 pts
Fundamentals Strong
Market Sentiment Neutral
Moat Narrow
Sector Rank #207/1021 (Top 20%)

Key Statistics

Market Data

Market Cap $1.6B
1D Range
12.42 13.02
52W Range
11.95 20.96

Valuation (TTM)

PE -28.30
PB 2.82
EV/EBITDA -37.22

Valuation (NTM)

Forward PE 2,440.27
Forward PEG 0.45
Price Target $39.00
Loading financial charts...

Profile

Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Si...

Sector Healthcare
Industry Biotechnology
Employees 108
IPO Date Jan 20, 2010
Fiscal Year July - June

Latest News

Mesoblast Showcased at ASX Premier Investor Day Event

1 day ago · globenewswire.com

Mesoblast Showcased at ASX Premier Investor Day Event
Mesoblast Posts $115 Million in Revenue, Sets Sights on 2027 Back Pain Trial Readout

4 days ago · marketbeat.com

Mesoblast Posts $115 Million in Revenue, Sets Sights on 2027 Back Pain Trial Readout
Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar

12 days ago · globenewswire.com

Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar
Mesoblast Board Changes

15 days ago · globenewswire.com

Mesoblast Board Changes
Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)

19 days ago · globenewswire.com

Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)
Mesoblast: Ryoncil Helps Fund Rexlemestrocel-L For Back Pain

29 days ago · seekingalpha.com

Mesoblast: Ryoncil Helps Fund Rexlemestrocel-L For Back Pain
Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product

2 months ago · globenewswire.com

Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript

3 months ago · seekingalpha.com

Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript
Mesoblast Reports Substantial Revenue Growth to US$120M

3 months ago · globenewswire.com

Mesoblast Reports Substantial Revenue Growth to US$120M
Mesoblast H2 Earnings Call Highlights

3 months ago · marketbeat.com

Mesoblast H2 Earnings Call Highlights

Earnings

Next Earnings
Mar 4, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
2
Consensus
Buy
Price Target
$39.00
Upside
+213.25%
Buy (2)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.